Results 181 to 190 of about 5,950 (190)

Postmarketing surveillance for drug abuse

Drug and Alcohol Dependence, 2003
Cynthia L Arfken
exaly  

Rivaroxaban postmarketing risk of liver injury

Journal of Hepatology, 2014
Stefan Russmann, Bruno Stieger, Gerd A Kullak-Ublick   +2 more
exaly  

Monitoring product safety in the postmarketing environment

Therapeutic Advances in Drug Safety, 2013
exaly  

The Food and Drug Administration Amendments Act and Postmarketing Commitments

JAMA - Journal of the American Medical Association, 2013
Kevin M Fain, G Caleb Alexander
exaly  

Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources

Seminars in Arthritis and Rheumatism, 2015
Jeffrey R Curtis, Susanna Perez-Gutthann, Samy Suissa   +2 more
exaly  

FDA Oversight of Postmarketing Studies

New England Journal of Medicine, 2017
exaly  

Postmarketing Adverse Events Related to the CardioMEMS HF System

JAMA Cardiology, 2017
Ersilia M Defilippis, Javed Butler
exaly  

Postmarketing surveillance study of a non-chlorofluorocarbon inhaler. Such studies initiated by manufacturer are designed to promote product.

BMJ (Clinical research ed.), 1999
openaire   +1 more source

Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999–2002

Current Medical Research and Opinion, 2009
exaly  

Postmarketing Trials for Rare Diseases

Science, 2012
exaly